Clinical trial

Lurasidone Low-Dose - High-Dose Study Study

NCT01821378

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-05-01

PhasePHASE3

Study timeline

Study start (unknown)2013-05-01Date precision: month

Registry last updated2016-07-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Interventions

LurasidoneDRUG

Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2DRUG

PlaceboDRUG

Sponsors & collaborators

Sumitomo Pharma America, Inc.lead sponsor

Mapped research locations

Saint PetersburgRussia4 BucharestRomania3 DallasTexas, United States2 San DiegoCalifornia, United States2 BogotáColombia2 HoustonTexas, United States1 Los AngelesCalifornia, United States1 PhiladelphiaPennsylvania, United States1 AtlantaGeorgia, United States1 MiamiFlorida, United States1 OrlandoFlorida, United States1 DenverColorado, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01821378 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.